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INTRODUCTION
The endogenous neurotransmitter acetylcholine (ACh) and the alkaloid nicotine bind nonselectively to nicotinic acetylcholine receptor (nAChR) subtypes and elicit a wide range of pharmacological actions. Nicotinic receptors in the central nervous system (CNS) may be involved in excitation, memory and learning [1, 2] . Nicotinic Acetylcholine Receptors (nAChRs) are pentameric membrane proteins belonging to the ligand-gated ion channel superfamily. A total of twelve (12) neuronal nAChR subunits are known that include nine (9) ( 2-10) and three (3) subunits ( 2-4) [1] . The nAChRs are composed of various combinations of these subunits that form homo or heteropentamers and are widely distributed throughout the central and peripheral nervous systems. Receptors composed of 4 and 2 subunits ( 4 2 subtype) and those containing the 7 subunits are *Address correspondence to this author at the Associate Professor of Medicinal Chemistry, Chair, Department of Pharmaceutical Sciences, Director of Graduate Studies, Temple University School of Pharmacy, USA; Tel: (215) 707-6924; E-mail: canney@temple.edu most commonly found in the CNS. Evidence suggests that nAChR subtypes may serve as novel drug targets for treatment of CNS disorders including Alzheimer's Disease (AD), Parkinson's Disease (PD), L-dopa induced dyskinesia, addiction, attention deficit hyperactivity disorder (ADHD) and major depressive disorders [2, 3] . Subtype selective nicotinic ligands have also been shown useful as pharmacological tools [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
Reports from this lab suggest that a quinuclidinecontaining, reverse-ester analog of acetylcholine, ethyl (3-quinuclidinyl)acetate (EQA), is an agonist at peripheral nicotinic acetylcholine receptors and may have antagonist properties at central nicotinic receptors [16, 17] . Using EQA as a lead compound, and considering SAR data from the literature, the goal of the present work was to design, synthesize and evaluate a series of 3-substituted quinuclidines as potential nicotinic ligands (Fig. 1) . The quinuclidine nucleus was chosen for several reasons. Firstly, it has been shown that the charge distribution of the protonated form of quinuclidine resembles that of the quaternary ammonium moiety of ACh more closely than the corresponding protonated piperidines Daniel J. Canney [18a] . Secondly, the nitrogen of quinuclidine is reversibly protonated at physiological pH. Therefore, the nucleus can mimic the quaternary ammonium group of ACh, but readily cross the blood brain barrier when substituted with appropriate R groups [18b] . Lastly, the quinuclidine nucleus has been used successfully as a scaffold in the design of numerous nicotinic ligands by us and others [16, 17, [19] [20] [21] [22] [23] [24] [25] . In fact our laboratory has reported 3-substitued quinuclidines with 3-substituents similar to those reported here that readily crossed the blood-brain barrier following i.p. administration in mice [16] .
The basic pharmacophoric requirements of cholinergic, and specifically nicotinic receptor ligands have been investigated for many years. Beers and Reich first reported that compounds binding to nicotinic receptors should possess a hydrogen-bond acceptor (HBA) group and a cationic center that was positioned 5.9 Å from the center of the van der Waals surface of the H-bond acceptor [26] . Later Sheridan et al used a distance geometry approach to determine that the distance between key functional groups for nicotine ligands was 4.8 Å [27] . Glennon et al assessed the various pharmacophore models that have been proposed for 4 2 subtype and suggested that newer vector models could account for the shortcomings of earlier models [28, 29] . Based on the structure-affinity literature currently available, it appears that ligands binding to the 4 2 and 7 receptor subtypes: should include a cationic center which is preferably nitrogenous; favor a HBA and/or electron rich moiety; should include a relative separation of cationic and HBA/ moieties of ca. 4-8Å; exhibit the tendency toward stereospecific interaction; may prefer some degree of HBA-cation co-planarity. The pharmacophoric requirements for nicotinic receptor ligands continue to evolve, and the currently available models are helpful when designing nicotinic ligands. The quinuclidine nucleus continues to be the focus of study in designing subtype specific nicotinic ligands as evidenced in recent literature reports [30, 31] . The compounds designed herein contain many of the pharmacophoric elements found in nicotinic receptor ligands including a cationic center (nitrogenous), HBA moieties, a separation of cationic and HBA/ moieties of ca. 4-8Å; and a chiral center (currently racemates). These racemic mixtures can later be separated and investigated individually if appropriate.
In most cases, molecular modeling studies demonstrate that the interatomic distances between the quinuclidine nitrogen and the H-bonding moieties of the series are consistent with distances reported for other centrally active nicotinic ligands ( Table 1) . We herein report the synthesis and evaluation of a series of 3-substituted ether and carbamate derivatives of quinuclidine as potential nicotinic ligands.
MOLECULAR MODELING
All molecular modeling was performed on a Silicon Graghics Personal IRIS 4D/25 workstation using the DREIDING II force field and biograf R (BIOSYM/Molecular Simulations, San Diego, CA). Individual models of the 3-substituted quinuclidines listed in Table 1 were constructed using the organic builder contained within the main biograf R program. Although each molecule carries a net total charge of zero, partial charges for each atom to be used in calculating the electrostatic contribution to the overall energy expression were derived by the charge equilibrium method [32] . Energy calculations for each molecule consisted of the following steps, (i) energy minimization to convergence according to the conjugate gradients methods developed by Fletcher and Reeves [33] (ii) quenched molecular dynamics calculations using the summed Verlet algorithm for 100 psec, [34] and (iii) energy minimization of the lowest energy structure obtained from the dynamics simulation. The details of the methods used here for the 3-substituted quinuclidines have been previously described [35, 36] . The proposed compounds were designed to meet the basic pharmacophoric requirements for known nicotinic ligands. The molecular modeling experiments suggest that the functional groups are positioned in the molecules such that they meet the distance requirements reported for nicotinic ligands (see Table 1 and results below). Based on these molecular modeling studies and the structure-activity data for known nicotinic ligands the proposed compounds were synthesized and evaluated as nicotinic ligands.
CHEMISTRY
Synthesis of various 3-substituted quinuclidines was affected as shown in Schemes 1-5 below, utilizing methods described in the literature or developed in our Laboratory. Compound 4, 3-Hydroxymethylquinuclidine, was identified as a critical precursor in the preparation of the target series. Two successful methods have been developed for the preparation of precursor 4. The first method utilized in the synthesis of compound 4 is shown in Scheme 1. The preparation of aldehyde 3 has been reported previously [12] . The Wittig reaction was viewed as a practical route for the preparation of enol ether 2 from the commercially available 3-quinuclidinone. Hydrolysis of 2 was accomplished by treating the enol ether with perchloric acid in chloroform. The desired aldehyde was obtained in an acceptable yield (42%). The final step in the sequence involved the reduction of the aldehyde to the corresponding alcohol using NaBH 4 in methanol. This reaction gave unexpectedly poor yields after repeated attempts. Due to the modest yield of the reaction sequence and the purification problems encountered, a different synthetic route was developed.
An alternative approach for the synthesis of compound 4 also utilized the Wittig reaction and is shown in Scheme 2. Preparation of 3-methylidenequinuclidine (5) from the commercially available 3-quinuclidinone proceeded smoothly. In contrast to the enol ether method above, the product could be readily purified in large quantities (1-2g) via distillation. Hydroboration and subsequent oxidation of compound 5 to the corresponding alcohol has been reported in the literature [38] and proceeded in good yield in our hands. The hydrophilic amino alcohol 4 was subjected to continuous extraction with ether (42 hours) to improve the recovery of product. The synthesis of the 3-(3-pyridyloxymethyl)qui-nuclidi- nes 6a, 6b and 6c, 3-(aryloxymethyl)quinuclidine 6d, and 6-methyl-3-(3-quinuclidinylmethyl)nicotinate, 6e is outlined in Scheme 3. In these reactions, the 3-hydroxymethylquinuclidine, 4 was coupled with the commercially available 3-pyridinols, phenol, or 6-methylnicotinic acid under Mitsunobu conditions to afford the target compounds 6a-6e in moderate yields. It is noteworthy to mention that 6e was found to be unstable over time as it hydrolyzed to the starting alcohol and acid. Compounds 9a and 9b were prepared in poor yields by reacting commercially available 3-quinuclidinol with 3-pyridinols under Mitsunobu reaction conditions (Scheme 4). These molecules are considered homologs of 6a and 6b since the distance between the key functional groups is one methylene unit. Altering the distance between the nitrogen and the hydrogen bond acceptor moieties of the proposed ligands might affect the binding of the ligands to the receptor.
The synthesis of carbamates 10, 11, 12 is shown in Scheme 5. They were prepared by treating phenyl isocyanate or isothiocyanate with the appropriate quinuclidinyl alcohols.
RESULTS
Numerous studies of the nicotinic receptor pharmacophore have illustrated the importance of a cationic center and an H-Bond acceptor moiety positioned at a critical distance from one another. Therefore, it was of interest to calculate the interatomic distances for the quinuclidine-based targets to determine if they fall within the range of interatomic distances reported for other high affinity nicotinic ligands. Reported distances were found to vary significantly with a lower limit of 4.9 Å (nicotine), an intermediate value of 5.5 Å (epibatidine) to an upper limit of 6.3 Å (A-85380). A model of each quinuclidine-based target was constructed and analyzed as described in the materials and methods section. In order to test the method, the interatomic distances of known high affinity nicotinic ligands were determined using this model and compared to the previously reported values. The results of these distance calculations are shown in Table 1 and are in moderate to good agreement with distances previously described [39, 40, 41] . The interatomic distances of N to N (6a-c, 6e and 10) or N to O 2 (6d, 6e and 10) for compounds 6a-e and 10 (6.6-9.5 Å) were found to be out of the range reported for known nicotinic receptor ligands. However, the N to O 1 distances calculated for 6a-e and 10 were found to be similar to the N to N distance of nicotine (4.8 Å). The N to N distances for compounds 9a, 9b, 11 and 12 were found to be within the range reported for numerous nicotinic ligands (5.5-6.3 Å) including epibatidine and A-85380. In compounds 11 and 12, the N to O 2 and N to S distances were found to be 5.35 and 5.7 Å respectively. Both of these values are also within an acceptable range. Based on these molecular modeling studies, the proposed compounds contain functional groups that are positioned such that they meet the distance requirements established for nicotinic ligands. The molecular modeling data were viewed as encouraging and led to the synthesis and testing of the target compounds.
Standard procedures for ligand binding studies using 3 H-(S)-Nicotine on membrane preparations were followed as described in the supplemental material [42] . The result of the 3 H-(S)-Nicotine binding assay is shown in Table 2 . Compounds 9a and 9b exhibit high affinity interactions with the 4 2 receptor subtype. Functional assays [43, 44] measuring neurotransmitter release relative to nicotine indicate that 9a and 9b act as partial agonists at CNS receptors with an efficacy of 28 and 40%, respectively (Fig. 2) . Both are potent partial activators of human muscle type receptors ( 1 1 ) with an E max value of 80% (76-87%) of that of 100 μM nicotine (represents 50% of maximal activation at this subtype) ( Table 3) . Together these results indicate a partial agonism at muscle type receptors (ca. 40%) with no significant activation of rat ganglion-type receptors ( 3 4 : asterisk indicates potential additional subunit that could partner to form the ganglionic receptor). The partial agonism inducing dopamine release from striatal synaptosomes( 4 2 6 4 2 3, and/or 6 2 3) suggest that these compounds may in addition be acting at the 4 2 and/or the 6 3* receptors [45] .
DISCUSSION
The interatomic distances ( Table 1 ) of known nicotinic ligands were compared to the newly designed ligands and were found to be in moderate to good agreement with some exceptions. For example, the N to N interatomic distances of (6a-c, 6e and 10) or N to O 2 (6d, 6e and 10) for compounds 6a-e and 10 (6.6-9.5 Å) were found to be out of the range reported for known nicotinic receptor ligands. However, the N to O 1 distances calculated for 6a-e and 10 were similar to nicotine (4.8 Å) but 6a, 6e and 10 exhibit poor affinity. The N to N distances for 9a, 9b, 11 and 12 were found to be within the range reported for epibatidine and A-85380 (5.7-6.2 Å) but several of these compounds lacked affinity (11, 12) . Within the series of test compounds prepared from 3-hydroxymethylquinuclidine (4), compounds 6b, 6c, and 6d had the highest, although moderate, affinity (551, 472, 300 nM, respectively). The only difference between compound 6a and 6b, 6c, and 6d is the presence or absence of a chlorine. The absence of a chlorine atom in 6a has adverse effects on binding. The chlorine may contribute to more favored conformations of the molecule and alter the orientation of the pyridine ring relative to the quinuclidine ring in those ligands.
Similar comments apply to the series of compounds prepared from 3-quinuclidinol. Compounds 9a and 9b has the highest affinity (48 and 42 nM, respectively) while 11 and 12 lacked affinity for the receptor. In this series, the presence or absence of a chlorine atom on the pyridinyl ring had little/no effect on binding. The fact that the pyridinyl ring has less flexibility due to its proximity to the quinuclidine nucleus may account for this observation. The results of these preliminary studies emphasize the need for more extensive modeling experiments/data when designing new nicotinic ligands. The usefulness of interatomic distance calculations alone has limited utility without consideration for other three dimensional considerations.
In conclusion, the present work is a continuation of our efforts to explore substituted quinuclidines as potential nicotinic ligands. Data provided through interatomic distance calculations for the proposed compounds provided limited help in predicting high affinity ligands. Of the series evaluated herein, two compounds were found to bind to the 4 2 subtype (nAChR) with nanomolar affinity. The present work suggests that these compounds act as partial agonists at CNS receptors and are worthy of further investigation.
MATERIALS AND METHODS
Proton Nuclear Magnetic Resonance spectra ( 1 H-NMR) were recorded on a 300 MHz General Electric QE-300 spectrometer at the Chemistry Department, Temple University. Tetramethylsilane (TMS) was used as an internal standard and chemical shifts are reported in parts per million ( ) downfield from TMS. Coupling constants are reported in Hertz. Mass spectra data, low-resolution mass spectroscopy (fast atom bombardment) (LRMS/FAB) and high-resolution mass spectroscopy (HRMS/FAB), were obtained with VG ZABHF high resolution mass spectrometer. Infrared spectra (IR) were determined on a Perkin-Elmer Model 1625 FT-IR instrument. Solid samples were examined as potassium bromide discs while liquids were examined as films between sodium chloride plates. Melting points were determined in open glass capillaries on a Thomas-Hoover Uni-melt Capillary melting point apparatus and are uncorrected. Elemental analyses were performed by Atlantic Microlabs, Inc., Atlanta, GA.
All reagents were purchased from Aldrich Chemical Co. Inc., Milwaukee, WI. Solvents of reagent and HPLC grade were obtained from Fisher Scientific Co., Malvern PA, and used without subsequent purification unless otherwise indicated. Organic solvents were purified when necessary by the methods described by D. D. Perrin and W. L. F. Armarego (Purification of Laboratory Chemicals; Pergamon: Oxford, 1988). Ether, as used in the text, corresponds to diethyl ether unless specifically mentioned. All final compounds were found to have purity greater than 95% based on HRMS and/or elemental analysis data.
General Chromatographic Procedures
All analytical thin layer chromatography (TLC) results were obtained using pre-coated silica gel plates (0.25mm) with fluorescent indicator, purchased from E. Merck, Darmstadt, Germany. All preparative TLC was performed on tapered silica gel plates, purchased from E. In the description of chromatographic techniques employed in this study, the solid phase and solvent mixture used will be designated as follows: (Silica, A).
Preparation of 3-Quinuclidinone (free base; 1)
The hydrochloride salt of 3-quinuclidinone (10 g, 0.062 mol) was dissolved in 45 ml of distilled water. The solution was made basic (pH 11-12) by adding sodium hydroxide solution (20%). The alkaline solution was extracted with 4 portions (25 mL) of methylene chloride and the organic phases were combined, and dried with sodium sulfate. The solvent was evaporated under reduced pressure (25 o C) to give 7.1 gm white solid of 3-quinuclidinone (yield: 91%), which was dried overnight in a vacuum desiccator. The product was stored under nitrogen prior to use. R f : 0.8 (silica, C).
Preparation of 3-Quinuclidinyl Aldehyde (3) via the Methyl Enol Ether (2)
This compound was prepared according to previously reported literature methods [12] . The glassware used in the reaction was dried overnight (18 hr) in an oven at 120 o C and assembled (hot) while flushing the system with nitrogen. Ether was dried by distillation under nitrogen from sodium benzophenoneketyl. Methoxymethyl triphenylphosphonium chloride (10.0 g, 0.029 mol) and dry ether (50 mL) were added to a three neck flask (200 mL) equipped with a dry source of nitrogen, a pressure equalizing dropping funnel, a stirring bar, and a rubber septum. Phenyllithium in ether (16 mL of a 1.8-M solution) was added dropwise via syringe at room temperature with stirring. As the ylide formed, the contents of the reaction flask developed a reddish-orange color. After complete addition of the phenyllithium, the mixture was stirred for an additional 15 minutes and then cooled to -35 o C (acetone / dry ice). The quinuclidinone (3.6 g, 0.029 mol) in dry ether was added slowly via the dropping funnel, at a rate that maintained the bath temperature at -35 o C. The mixture was allowed to come to room temperature slowly and thereafter stirred overnight under nitrogen. The reaction mixture was filtered through Celite-545 using a sintered glass funnel, the filtrate cooled to precipitate triphenylphosphine oxide and lithium chloride and refiltered. The solvent was removed under vacuum. The residual oil was chromatographed on silica gel and eluted with solvent mixture B. The oil was further purified by vacuum distillation to yield 2.5 g (56 %) of the enol ether (2) The enol ether (2.5 g) in chloroform was treated with concentrated perchloric acid (200 drops; 8 drops per 100 mg of enol ether) added dropwise over 10 minutes at room temperature. The mixture was stirred for an additional 15 minutes, placed in an ice bath and basified with saturated sodium carbonate solution. The phases were separated, the aqueous layer extracted with fresh chloroform, the organic layers combined, dried over sodium sulfate, filtered, and the solvent removed under vacuum to yield 0.95 g (42%) of the aldehyde (3) as a yellow oil which was used immediately in the next reaction. R f : 0.3 (silica, B). 
Preparation of 3-Hydroxymethylquinuclidine (4) via the Aldehyde (3)
The aldehyde (3) (0.42 g, 3.0 mmol) was dissolved in ethanol (50 mL) was transferred to a three-neck flask (200 mL) equipped with a pressure equalizing dropping funnel, a condenser, a stirring bar, and a rubber septum and was cooled to 0 o C by immersion in a crushed ice-water bath. Sodium borohydride (0.15 g, 3.9 mmol) in ethanol (50 mL) was added slowly from the funnel with vigorous stirring over a period of 30 minutes. The reaction was allowed to warm to room temperature and stirred for an additional 2 hours. The solution was then cooled to 0 o C and neutralized with concentrated hydrochloric acid. The ethanol was removed under vacuum, and the residual mixture was basified with saturated potassium carbonate solution. The alkaline solution was extracted with 4 portions (25 mL) of methylene chloride, the organic phases combined, dried with sodium sulfate, and the solvent was evaporated under reduced pressure to give the alcohol, 3-hydroxymethylquinuclidine (4), in low yield.
Preparation of 3-methylidenequinuclidine (5)
The reaction was carried out under nitrogen using previously dried glassware, syringes, needles and spatulas. Methyltriphenylphosphonium bromide (20.32 g, 0.057 mol) and dry tetrahydrofuran (THF; 150 mL) were added to 3-necked flask (500 mL) equipped with a magnetic stirrer, dropping funnel, nitrogen inlet and a septum. A 1.8 M solution of phenyl lithium in ether (30 mL, 0.054 mol) solution via syringe was added dropwise to the mixture of methyltriphenylphosphonium bromide in THF (slightly soluble). During the addition of phenyllithium, evolution of gas and a slight increase in temperature was observed. The color of the mixture turned form a brownish red color to a clear solution after complete addition of phenyllithium. The clear solution was stirred at room temperature for an additional 15 minutes, and then was cooled to 0 o C (ice bath water). Quinuclidinone in dry THF (7.0 g, 0.056 mol) was added slowly via the dropping funnel at a rate that maintained the bath temperature at 0 o C. The reaction was allowed to warm to room temperature and stirred overnight under nitrogen (20 hours). The followed day, the reaction mixture was filtered through coarse filter paper (Qualitative 1, Whatman). The solvent was removed under vacuum to yield a red sticky residue (25 g ) that contains triphenylphosphine oxide and lithium chloride. The residue was dissolved in methylene chloride (20 mL), chilled in an ice-water bath, and 10% hydrochloric acid was added until the solution reached pH < 2. The aqueous phase was collected and washed with 4 portions of methylene chloride (50 mL). The chilled aqueous phase was made basic using sodium hydroxide until the solution reached a pH >10. The alkaline solution was extracted with ether (3 100 mL). The organic phases were combined, dried under sodium sulfate, and concentrated under reduced pressure to yield the crude product. The product was purified by vacuum distillation to yield the olefin (5) 
Treatment of Picric Acid
The supernatant water was decanted from the commercial picric acid, and the solid residue was washed three times with an excess of ethanol. The solid that remained was stored under ethanol in a tightly stoppered bottle. Picric acid should not be allowed to become dry (detonation) when exchanging water for ethanol and should be handled with care (toxicity; absorption through the skin).
Preparation of 3-Hydroxymethylquinuclidine (4) via the N-borate Complex
A dry three-neck, round-bottomed flask (250 mL) was fitted with a reflux condenser, thermometer, magnetic stirring bar and a septum. A static nitrogen pressure was maintained during the course of the reaction. The olefin (5) (3.45 g, 0.028 mol) in dry THF (100 mL) was added to the flask via a syringe. The flask was immersed in an ice bath (0 o C), and 1.00 M borane-THF complex (60 mL) was added dropwise over a period of 0.5 hour to the stirred solution. The reaction mixture was stirred and the temperature maintained at 40 o C for 14 hours. Water (10mL) was added slowly at room over several minutes, and the mixture was allowed to stir at room temperature until hydrogen no longer evolved from the reaction. The organoborane thus formed was oxidized at 40 -50 o C by the addition of a 3 M sodium hydroxide solution (15 mL, excess), followed by the careful dropwise addition of 35% hydrogen peroxide (15 mL). The mixture was stirred for additional two hours. Potassium carbonate was added to saturate the aqueous phase and the upper THF layer was separated and collected, washed with brine, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to afford solid 3-hydroxymethylquinuclidine-N-boranate (3.69 gm; 85% yield). The product was used directly in the following reaction. R f : 0.9 (silica, B).
The N-borate complex (3.60 g) dissolved in 1.8 N aqueous HCl (30 mL) was stirred for 18 hours at room temperature, cooled to 0 o C, and made alkaline with potassium hydroxide solution (20%). The resulting solution was placed in an Aldrich convertible liquid/liquid continuous extractor (1000 mL) and ether was used as the extraction solvent. Continuous extraction over 3 days afforded the gum-like alcohol 3-hydroxy-methylquinuclidine (4) as a gummy semisolid (2.70 gm; 82 % yield). Rf: 0.25 (silica, A). 1 The following procedure was used to prepare the picric salt of compound 4. Compound 4 (700 mg, 5.0 mmol) was dissolved in a minimum quantity of acetone (less than 0.5 mL) and a solution of picric acid (wet with ethanol, ca. 1.0 gm) in acetone was added dropwise to the stirring solution at room temperature. Crystallization of the product was accomplished by the addition of ether (5 mL) to give a yellow solid that was filtered and washed thoroughly with ether. The picrate salt (1.56 gm; yield: 85%) was recrystallized from ethanol.
mp 
General Method for Preparation of 6a-6e Using Alcohol 4 as Starting Material
The alcohol (4) (5.0 mmol), triphenylphosphine (7.5 mmol) and 3-hydroxypyridine (7.5 mmol) were dissolved in anhydrous THF (30 mL) at room temperature. After stirring for 15 minutes, the mixture was chilled to 0 o C (ice-water bath), and diethyl azodicarboxylate (DEAD; 1.5 mL, 7.5 mmol) was added dropwise to the reaction. The resultant solution was stirred at room temperature until TLC indicated that all of 4 was consumed (14 hours).
Following removal of solvent in vacuo, the residue was treated at 0 o C with10% hydrochloric acid until the solution was acidic (pH < 2). The acidic aqueous phase was extracted with methylene chloride (4 25 mL) to remove triphenylphosphine oxide. The aqueous phase was collected, made strongly basic (pH 11-12) with sodium hydroxide solution (20%) and the alkaline solution was extracted with methylene chloride (4 25 mL). The organic phases were combined, evaporated in vacuo, and the residue was purified by flash silica gel column chromatography. Elution with solvent mixture A provided the products 6a -6e. 
3-(3-quinuclidinylmethoxy)pyridine

2-chloro-3-(3-quinuclidinylmethoxy)pyridine HCl (6c)
Elution with solvent mixture A provided the product, 2-chloro-3-(3-quinuclidinylmethoxy)pyridine (6c) (560 mg; 44% yield). R f : 0.45 (silica, A). Compound 6c (200 mg, 0.80 mmol) was dissolved in ethanol and hydrochloric acid in diethyl ether was added dropwise to a stirring solution at ambient temperature. Solvent was evaporated and the resultant pale yellow precipitate was triturated with three portions of ether to afford the product as a hygroscopic solid (60 mg, yield: 26% 
Preparation of 3-(3-quinuclidinol)pyridine (9a)
3-quinuclidinol (890 mg, 7.0 mmol), triphenylphosphine (2400 mg, 9.0 mmol) and 3-hydroxypyridine (860 mg, 9.0 mmol) were dissolved in anhydrous THF (30 mL) at room temperature. After stirring for 15 minutes, the mixture was chilled to 0 o C (ice-water bath), diethyl azodicarboxylate (DEAD) (1.8 mL, 9.0 mmol) was added dropwise to the reaction. The resultant solution was stirred at room temperature until TLC indicated that all of 4 was consumed (14 hours).
Following removal of solvent in vacuo, the residue was treated at 0 o C with10% hydrochloric acid until the solution was acidic (pH < 2). The acidic aqueous phase was extracted with methylene chloride (4 25 mL) to remove triphenylphosphine oxide. The aqueous phase was collected, made strongly basic (pH 11-12) with sodium hydroxide solution (20%) and the alkaline solution was extracted with methylene chloride (4 25 mL). The organic phases were combined, evaporated in vacuo,and the residue was purified by flash silica gel column chromatography. Elution with solvent mixture A provided the mixture of product, 3-(3-quinuclidinol)pyridine (9a) and side product (DEAD-relative complex). The product (9a) (50 mg; overall yield: 3.5%) was finally isolated by the preparative TLC plate, eluting with solvent mixture E. R f : 0.75 (silica, E). 1 
Preparation of 3-(3-quinuclidinol)pyridine (9b)
3-quinuclidinol (890 mg, 7.0 mmol), triphenylphosphine (2400 mg, 9.0 mmol) and 5-chloro-3-pyridinol (1170 mg, 9.0 mmol) were dissolved in anhydrous THF (30 mL) at room temperature. After stirring for 15 minutes, the mixture was chilled to 0 o C (ice-water bath), diethyl azodicarboxylate (DEAD) (1.8 mL, 9.0 mmol) was added dropwise to the reaction. The resultant solution was stirred at room temperature until TLC indicated that all of 4 was consumed (14 hours).
Following removal of solvent in vacuo, the residue was treated at 0 o C with10% hydrochloric acid until the solution was acidic (pH<2). The acidic aqueous phase was extracted with methylene chloride (4 25 mL) to remove triphenylphosphine oxide. The aqueous phase was collected, made strongly basic (pH 11-12) with sodium hydroxide solution (20%) and the alkaline solution was extracted with methylene chloride (4 25 mL). The organic phases were combined, evaporated in vacuo,and the residue was purified by flash silica gel column chromatography. Elution with solvent mixture A provided the mixture of product, 3-(3-quinuclidinol) pyridine (9b) and side product (DEADrelative complex). The product (9b) (41 mg; overall yield: 2.5%) was finally isolated by the preparative TLC plate, eluting with solvent mixture E. R f : 0.85 (silica, E). 1 
Preparation of 3-N'-phenylcarbamylmethylquinuclidine (10)
Phenyl isocyanate (0.6 ml, 16.96 mmol) was added via a syringe to the alcohol (4) (500 mg, 3.5 mmol) stirring in absolute chloroform (25 mL) under nitrogen. The reaction mixture was stirred at room temperature for 16 hours, evaporated under reduced pressure, and chromatographed on silica gel column with solvent mixture A. Evaporation of the solvent under reduced pressure and recrystallization from petroleum ether yielded the product, 3-N'-phenylcarbamylmethylquinuclidine (10) as a white solid (654 mg) in 72% yield. Rf: 0.6 (silica, A 
Preparation of 3-N'-phenylcarbamylquinuclidine (11)
Phenyl isocyanate (1.2 ml, 33.92 mmol) was added via a syringe to 3-quinuclidinol (1.0 g, 7.86 mmol) stirring in absolute chloroform (25 mL) under nitrogen. The reaction mixture was stirred at room temperature for 16 hours, evaporated under reduced pressure, and chromatographed on silica gel column with solvent mixture A. Evaporation of the solvent under reduced pressure and recrystallization from petroleum ether yielded the product, 3-N'-phenylcarbamylquinuclidine (11) as a white solid (1.6 g) in 83% yield. R f : 0.6 (silica, A). 
Preparation of 3-N'-phenylthiocarbamylquinuclidine (12)
Phenyl isothiocyanate (1.5 ml, 33.92 mmol) was added via a syringe to 3-quinuclidinol (1.0 g, 7.86 mmol) stirring in absolute chloroform (25 mL) under nitrogen. The reaction mixture was stirred at room temperature for 16 hours, evaporated under reduced pressure, and chromatographed on silica gel column with solvent mixture A to yield the product, 3-N'-phenylthiocarbamylquinuclidine (12) as a yellow oil (495 mg) in 24% yield. R f : 0.6 (silica, A 
Binding and Functional Studies
3 H-(S)-Nicotine Binding. Standard procedures for ligand binding studies on membrane preparations were followed [42] . Radiolabelled ligands were purchased from New England Nuclear (NEN).
Ion Flux in TE671/RD and PC 12 Cells
Cells of the TE671/RD human clone, and the PC12 rat pheochromocytoma, were used according to routine protocols [43] . Following the radioisotope loading period (37°C), cells were washed twice with PBS and ligands were added to cells plated on micro-wells. The supernatant was collected following a 4-minute exposure. Levels of non-specific ion flux were equivalent, whether defined using samples containing agonist plus 100 M d-tubocurarine or using blank samples that contained no agonist, and specific nAChR function was defined as total, experimentally-determined ion flux in the presence of agonist +/-test compounds minus nonspecific ion flux.
Neurotransmitter Release from Brain Synaptosomes
Neurotransmitter release was measured using techniques similar to those previously published [44] . Rat brain synaptosomes were prepared as follows. Female Sprague Dawley rats (100-200 g) were killed by decapitation after anesthesia with 70% C0 2 . Brains are dissected, and hippocampus, striatum, and thalamus isolated, and homogenized in 0.32 M sucrose containing 5 mM HEPES pH 7.4 using a glass/glass homogenizer. The tissue was then centrifuged for 1000 x g for 10 minutes and the pellet discarded. The supernatant was centrifuged at 12000 x g for 20 minutes. The resultant pellet was re-suspended in perfusion buffer (128 mM NaCl, 1.2 mM KH 2 PO 4 , 2.4 mM KCl, 3.2 mM CaCl 2 , 1.2 mM MgSO 4 , 25 mM HEPES, l mM Ascorbic acid, 0.01 mM pargylineHCl and 10 mM glucose pH 7.4) and centrifuged for 15 minutes at 25000 x g. The final pellet was re-suspended in perfusion buffer and placed in a water bath (37°C) for 10 minutes. Radiolabeled neurotransmitter is added (30 μL 3 H DA, 20 μL 3 H NE, 10 μL 3 H glutamate) to achieve a final concentration of 100 nM, vortexed and placed in a water bath for additional 10 minutes. Tissue-loaded filters are placed onto 11-mm diameter Gelman A/E filters on an open-air support. After a 10-minute wash period, fractions are collected to establish the basal release and agonist applied in the perfusion stream. Further fractions were collected after agonist application to re-establish the baseline. The perfusate was collected directly into scintillation vials and released radioactivity was quantified using conventional liquid scintillation techniques. Release of neurotransmitter was determined in the presence of 10μM of various ligands and was expressed as a percentage of release obtained with a concentration of 10μM (S)-(-)-nicotine or 300μM TMA resulting in maximal effects.
